Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, University of Washington to Co-develop Array-Based Dx for Lymphoma

NEW YORK, Sept. 11 (GenomeWeb News) - CombiMatrix and the Universityof Washingtonplan to co-develop a microarray-based test for diagnosing lymphoma, the two groups said today.

A team of university researchers led by Daniel Sabath and Stephen Schmechel, at the Departments of Laboratory Medicine and Pathology in the Schoolof Medicine, claimed to have identified a subset of genes whose expression pattern can "distinguish the various lymphoma types." The goal of the collaboration, then, is to harness those data and develop array-based diagnostics that detect lymphomas and predict clinical outcome.

To help develop and commercialize a potential product, CombiMatrix has penned an agreement with RationalDiagnostics. Last year, Seattle-based RationalDiagnostics, which was co-founded by Sabath and Schmechel, signed a deal with the Universityof Washingtonand the WashingtonTechnologyCenterthat ultimately helped uncover ways of using microarrays to diagnose lymphoma.

 

Existing methods of diagnosing lymphoma, which are based on examining tissue biopsies for a small number of markers, are often inaccurate and offer physicians "limited information" about the expected course of a patient's cancer progression.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.